Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Cohort Study of Adjuvant Therapy With Naratinib in HER2 Positive Early Breast Cancer

NCT06693024 is registered in ClinicalTrials.gov with Shu Wang as lead sponsor.

NCT NCT06693024
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06693024 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Cohort Study of Adjuvant Therapy With Naratinib in HER2 Positive Early Breast Cancer
Lead sponsor
Shu Wang
Phase
Observational
Overall status
Recruiting
Start date
January 1, 2019
Completion date
December 31, 2031
Enrollment
2,806 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

her2-positive breast cancer